OLD Mission Capital LLC Buys Shares of 1,868 Krystal Biotech, Inc. (NASDAQ:KRYS)

OLD Mission Capital LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,868 shares of the company’s stock, valued at approximately $293,000.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after purchasing an additional 28,707 shares during the period. State Street Corp lifted its stake in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after buying an additional 11,411 shares during the period. Franklin Resources Inc. grew its stake in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock valued at $38,095,000 after buying an additional 2,954 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Down 3.1 %

Shares of KRYS stock opened at $166.01 on Tuesday. The company has a market cap of $4.78 billion, a P/E ratio of 55.52 and a beta of 0.75. The firm has a fifty day moving average price of $173.40 and a 200 day moving average price of $172.87. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the prior year, the firm posted $0.30 EPS. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. On average, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

KRYS has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. Finally, Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).